Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected

 

IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be presented today at an oral presentation during the American Society of Cell & Gene Therapy 27th Annual Meeting in Baltimore. Prime Medicine recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for PM359 for the treatment of CGD.

"These data are incredibly exciting—showing for the first time that Prime Editing can not only correct the disease-causing mutation of CGD in human blood stem cells, but that those cells can produce neutrophils with restored immune function and healthy activity following engraftment in rodents with no off-target edits observed," said Jennifer Gori, Ph.D., Vice President, Head of Hematology and Immunology at Prime Medicine. "Further, we were able to demonstrate clinical-scale production of Prime Edited blood stem cells, supporting our planned advancement into the clinic with PM359."

CGD is a rare inherited disease that leads to recurrent, debilitating and often life-threatening infections. CGD is caused by mutations in any one of the subunits comprising the NADPH oxidase complex, an enzyme that kills bacteria and fungi to control infection. CGD causative mutations are estimated to occur in between one in 100,000 and one in 200,000 births in the U.S., and most children are diagnosed within the first three years of life. The second most common form of CGD, which represents approximately 25% of cases, is caused by loss-of-function mutations in both copies of the NCF1 gene encoding the p47phox protein.

Prime Medicine is advancing an ex vivo Prime Editing program, PM359, that aims to correct the predominant mutation in NCF1 in CGD patient CD34+ hematopoietic stem cells (HSCs) and restore NADPH oxidase function.

In today's presentation at ASGCT, Prime Medicine highlighted data from a series of in vivo non-clinical studies using human CGD patient CD34+ HSCs. Notably, findings demonstrated restoration of neutrophil function after stem cell engraftment in mice, as well as the ability to scale up production of Prime Edited cells to clinical scale. Detailed findings are as follows:

• Prime Editing precisely corrected the CGD causative mutation in greater than 75% of CGD patient CD34+ cells
• The CGD causative mutation is corrected in ≧80% Prime Edited CGD patient CD34+ cells that engraft the bone marrow in a mouse model
• NADPH oxidase activity was restored in bone marrow neutrophils in the mice engrafted with Prime Edited CGD patient CD34+ cells
• Interferon-regulated gene expression in Prime Edited CGD patient cells was reduced compared to unedited CGD patient cells and similar to healthy donor cells, suggesting Prime Editing restored cells to healthy state
• No unintended or off-target edits were detected in engrafted Prime Edited CGD patient CD34+ cells
• Process development supported reproducible and efficient manufacturing of clinical-scale healthy donor drug products (HDDP) with high purity, viability, potency and Prime Editing efficiency
  • Long-term engraftment of HDDP was achieved with human multilineage blood production and biodistribution maintained
    
     

"We are very pleased to report these data from our PM359 program in CGD, which supported the basis of our IND application package to the U.S. FDA," said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine. "With our recent IND clearance, we are working efficiently to move forward with our Phase 1/2 clinical trial of PM359, from which we expect to report first-in-human data in 2025. This is a significant moment for Prime Medicine and the gene editing field, and I am grateful for the unwavering commitment of my colleagues to advance this program. I look forward to the planned evaluation of PM359 in the clinic so that we can truly realize the impact this novel technology may have on patients in need of new treatments."